The Trips Agreement Allows Developing Countries To Produce Generic Drugs

Azevedo said WTO agreements should not operate in a vacuum and support development and better livelihoods around the world and complement other goals such as environmental policy and public health. The legal problem for exporting countries was resolved on 30 August 2003, when WTO members agreed on legislative changes to facilitate the importation of cheaper generic medicines from the Dertakt licence if they are unable to produce the medicines themselves. Developing countries are expected to have better access to generic medicines following changes made by the World Trade Organization at the end of January. As far as we know, the Doha Declaration solution has only been used once. In July 2007, Rwanda informed the WTO that it intended to import a fixed-dose antiretroviral combination drug produced by the Canadian generic drug manufacturer Apotex. In September 2007, Apotex obtained a compulsory licence from Canadian authorities14 Between 2008 and 2010, Apotex exported three batches of antiretroviral drugs from Canada to Rwanda through this system.15 several comments questioned the effectiveness and sustainability of the system.16-20 The TRIPS Agreement allows compulsory licensing as part of the overall balance between promoting access to the existing arz. 1992, 1995, 1994, 1994, 1994, 1994, 1 Article 31 of the Agreement allows compulsory licences and the use by the State of a patent without the authorisation of its holder, under a number of conditions aimed at protecting the legitimate interests of the patent proprietor. The possibility of issuing a compulsory licence in accordance with Article 31 for the purpose of manufacture or import shall be available to all Members. It can cover any products or technologies needed to treat a disease or fight a pandemic.

The WTO announced on 23rd January that the required two-thirds majority of its 164 member states had voted in favour of ratifying the amendment to the ad hoc agreement (Trade Related Aspects of Intellectual Property Rights). This is the first time that a WTO agreement has been revised since the organization opened in 1995. The Doha Declaration solution is laborious to implement, but it gives countries – even those without domestic production capacity – the power to threaten to use a compulsory licence. This can have an influence on prices. For example, sofosbuvir is a relatively new and highly effective treatment for hepatitis C, but its high price in some countries has proven controversial. Sofosbuvir was marketed in 2007. According to Iyengar and colleagues, the price of Sofosbuvir in 2015 was $64,680 $US per treatment in the United States and India was $539.23 In 2015, no country had issued a compulsory license for Sofosbuvir. . .

.